These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 8960826)
41. Decreased protein C activation in patients with fulminant hepatic failure. Yamaguchi M; Gabazza EC; Taguchi O; Yano Y; Ikoma J; Kaito M; Kojima Y; Imoto I; Satomi A; D'Alessandro-Gabazza CN; Hayashi T; Moriwaki H; Suzuki K; Adachi Y Scand J Gastroenterol; 2006 Mar; 41(3):331-7. PubMed ID: 16497622 [TBL] [Abstract][Full Text] [Related]
42. Morning hypercoagulability and hypofibrinolysis. Diurnal variations in circulating activated factor VII, prothrombin fragment F1+2, and plasmin-plasmin inhibitor complex. Kapiotis S; Jilma B; Quehenberger P; Ruzicka K; Handler S; Speiser W Circulation; 1997 Jul; 96(1):19-21. PubMed ID: 9236409 [TBL] [Abstract][Full Text] [Related]
43. Increased thrombogenesity in patients with cyanotic congenital heart disease. Kajimoto H; Nakazawa M; Murasaki K; Mori Y; Tanoue K; Kasanuki H; Nakanishi T Circ J; 2007 Jun; 71(6):948-53. PubMed ID: 17526995 [TBL] [Abstract][Full Text] [Related]
44. Enhanced anticoagulant response to activated protein C in patients with IDDM. Krugluger W; Kopp HP; Schernthaner G; Hopmeier P Diabetes; 1995 Sep; 44(9):1033-7. PubMed ID: 7657025 [TBL] [Abstract][Full Text] [Related]
45. Plasma levels of thrombomodulin, plasminogen activator inhibitor-1 and fibrinogen in elderly, diabetic patients with depressive symptoms. Gorska-Ciebiada M; Saryusz-Wolska M; Borkowska A; Ciebiada M; Loba J Aging Clin Exp Res; 2016 Oct; 28(5):843-51. PubMed ID: 26613755 [TBL] [Abstract][Full Text] [Related]
46. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome. Oral B; Mermi B; Dilek M; Alanoğlu G; Sütçü R Gynecol Endocrinol; 2009 Feb; 25(2):110-6. PubMed ID: 19253106 [TBL] [Abstract][Full Text] [Related]
47. [Plasminogen activator inhibitor (PAI-1) and markers of endothelial dysfunction in patients with diabetes mellitus]. Galajda P; Martinka E; Baláz D; Stasko J; Kerný J; Planková E; Mokán M; Kubisz P Vnitr Lek; 1997 Nov; 43(11):744-7. PubMed ID: 9650506 [TBL] [Abstract][Full Text] [Related]
48. Vascular involvement in Behçet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Espinosa G; Font J; Tàssies D; Vidaller A; Deulofeu R; López-Soto A; Cervera R; Ordinas A; Ingelmo M; Reverter JC Am J Med; 2002 Jan; 112(1):37-43. PubMed ID: 11812405 [TBL] [Abstract][Full Text] [Related]
52. Circulating thrombomodulin and hematological alterations in type 2 diabetic patients with retinopathy. Fujiwara Y; Tagami S; Kawakami Y J Atheroscler Thromb; 1998; 5(1):21-8. PubMed ID: 10077454 [TBL] [Abstract][Full Text] [Related]
53. Influence of ramipril on the course of plasma thrombomodulin in patients with diabetes mellitus. Borcea V; Morcos M; Isermann B; Henkels M; Ziegler S; Zumbach M; Amiral J; Längst KD; Seiz W; Ziegler R; Wahl P; Nawroth PP Vasa; 1999 Aug; 28(3):172-80. PubMed ID: 10483322 [TBL] [Abstract][Full Text] [Related]
54. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. Esmon CT FASEB J; 1995 Jul; 9(10):946-55. PubMed ID: 7615164 [TBL] [Abstract][Full Text] [Related]
55. Increased levels of N(epsilon)-(carboxymethyl)lysine and N(epsilon)-(carboxyethyl)lysine in type 1 diabetic patients with impaired renal function: correlation with markers of endothelial dysfunction. Lieuw-A-Fa ML; van Hinsbergh VW; Teerlink T; Barto R; Twisk J; Stehouwer CD; Schalkwijk CG Nephrol Dial Transplant; 2004 Mar; 19(3):631-6. PubMed ID: 14767019 [TBL] [Abstract][Full Text] [Related]
57. Effects of ingested fructose and infused glucagon on endogenous glucose production in obese NIDDM patients, obese non-diabetic subjects, and healthy subjects. Paquot N; Schneiter P; Jéquier E; Gaillard R; Lefèbvre PJ; Scheen A; Tappy L Diabetologia; 1996 May; 39(5):580-6. PubMed ID: 8739918 [TBL] [Abstract][Full Text] [Related]
58. Effect of cilostazol on soluble adhesion molecules and platelet-derived microparticles in patients with diabetes. Nomura S; Shouzu A; Omoto S; Hayakawa T; Kagawa H; Nishikawa M; Inada M; Fujimura Y; Ikeda Y; Fukuhara S Thromb Haemost; 1998 Sep; 80(3):388-92. PubMed ID: 9759615 [TBL] [Abstract][Full Text] [Related]
59. Thrombogenic factors are related to urinary albumin excretion rate in type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetic patients. Knöbl P; Schernthaner G; Schnack C; Pietschmann P; Griesmacher A; Prager R; Müller M Diabetologia; 1993 Oct; 36(10):1045-50. PubMed ID: 8243853 [TBL] [Abstract][Full Text] [Related]